Excretion of Mast Cell Mediators in Children with Allergic Disorders

Overview

About this study

The aim of this study is to examine the role of mast cell mediators in children with allergic disorders in a two part study. Part 1 of the study will prospectively obtain the values of mast cell mediators, including 2,3 dinor 11β-PGF2α, n-MH, and LTE4 in the urine of a healthy pediatric reference population. Part 2 of the study will prospectively evaluate the urine concentrations of mast cell mediators in a cohort of pediatric allergic disorder patients including asthma, allergic rhinoconjunctivitis, eczema, urticaria, systemic anaphylaxis, and mast cell disorders, as well as POTS (postural orthostatic tachycardia syndrome). Comparisons of these values in the disease cohort will be made utilizing the pediatric expected reference intervals established in Part 1. Further analysis will determine if one or several urine mast cell mediators are elevated in a particular allergic disorder.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Part 1

  • Children (<18 years of age)

Part 2

  • Age <18 years old
  • Allergic disorders: asthma, eczema, allergic rhinitis, IgE-mediated food allergies, eosinophilic esophagitis, chronic urticaria
  • Mast cell disorders: Urticaria pigmentosa, mastocytoma, mast cell activation disorders
  • Autonomic dysfunction/POTS

Exclusion Criteria:

Part 1

  • Age > 18 years old
  • Allergic disorder: asthma, eczema, allergic rhinitis, IgE-mediated food allergies, eosinophilic esophagitis, chronic urticaria
  • Mast cell disorders: Urticaria pigmentosa, mastocytoma, mast cell activation disorders
  • On medications such as antihistamines, montelukast, NSAIDs

Part 2

  • None

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Anupama Ravi, M.D.

Open for enrollment

Contact information:

Kay Bachman R.N., C.C.R.C.

(507) 284-5689

bachman.kay@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available